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Human sera contain high levels of natural antibody (Ab) to Gala1-3Gal, a terminal glycosidic structure
expressed on the surface of cells of mammals other than Old World primates. Incorporation of this determi-
nant onto retroviral membranes by passage of viruses in cells encoding a-1-3-galactosyltransferase (GT)
renders retroviruses sensitive to lysis by natural Ab and complement in normal human serum (NHS). Plasma
membrane-budding viruses representing four additional virus groups were examined for their sensitivities to
serum inactivation after passage through human cell lines that lack a functional GT or human cells expressing
recombinant porcine GT. The inactivation of lymphocytic choriomeningitis virus (LCMV) by NHS directly
correlated with host modification of the virus via expression of Gala1-3Gal and was blocked by incorporation
of soluble Gala1-3Gal disaccharide into the inactivation assay. GT-deficient mice immunized to make high
levels of Ab to Gala1-3Gal (anti-Gal Ab) were tested for resistance to LCMV passaged in GT-expressing cells.
Resistance was not observed, but in vitro analyses of the mouse immune sera revealed that the antiviral activity
of the sera was insufficient to eliminate LCMV infectivity on its natural targets of infection, macrophages,
which express receptors for Ab and complement. Newcastle disease virus and vesicular stomatitis virus (VSV)
were inactivated by NHS regardless of cell passage history, whereas Sindbis virus (SV) passaged in human cells
resisted inactivation. Both VSV and SV passaged in Gala1-3Gal-expressing human cells incorporated this
sugar moiety onto their major envelope glycoproteins. SV passaged in mouse cells expressing Gala1-3Gal was
moderately sensitive to inactivation by NHS. These results indicate that enveloped viruses expressing Gala1-
3Gal differ in their sensitivities to NHS and that a potent complement source, such as that in NHS, is required
for efficient inactivation of sensitive viruses in vitro and in vivo.
Natural immunity to viruses can be mediated by humoral
components of the immune system, including natural antibody
(Ab) and complement (11). The complement system is gener-
ally activated by Ab that has bound to its target antigen, but it
can also be activated by many membrane structures indepen-
dently of Ab. For example, neutralization of retroviruses and
paramyxoviruses has been reported to be mediated by Ab-
independent mechanisms via the classical and alternative com-
plement pathways, respectively (42, 44, 45). Retroviruses di-
rectly activate human complement through direct interaction
of C1q with the murine retrovirus p15e or with the human
retrovirus gp41 transmembrane protein (5, 13). Human and
nonhuman complement sources act differently; although both
human and guinea pig C1q bind the Moloney leukemia virus
p15e, the human C1s is required to initiate the complement
cascade (4).
Viruses act differently in their sensitivities to human com-
plement. Murine retroviruses passaged through mouse cells
are reported to activate complement sufficiently for it to lyse
the virions, releasing virion RNA and reverse transcriptase (34,
44, 45). Conversely, activation of complement by human ret-
roviruses passaged through human cells is reported to not be
sufficient to lyse the virions. However, the deposition of com-
plement on the human retroviruses results in opsonization of
the virions and enhanced infection of complement receptor
(CR)-expressing cells (20, 38).
It is clear that Ab is not required for the activation of human
complement by retroviruses, because complement activation
has been shown with purified viruses or viral proteins and
purified complement components (4, 5, 10). It is also unlikely
that Ab is essential for the reduction in infectivity and the lysis
of nonhuman retroviruses by complement, as there are numer-
ous reports that human serum can inactivate and lyse nonhu-
man retroviruses passed through human cells (34, 45), through
other Old World primate cells (16, 34, 45), or through nonpri-
mate cells lacking reactivity with Ab in human serum (44). In
addition, agammaglobulinemic human sera retain the capacity
to lyse murine retroviruses (44, 45). Nevertheless, Ab can ac-
celerate the dynamics of complement deposition on mem-
branes, and recent work has indicated that the level of retro-
virus inactivation by normal human serum (NHS) can be
greatly augmented by natural Ab if the viruses are passed
through appropriate cell lines that express the epitope to which
the Ab is directed (28, 30, 36).
Human sera contain very high levels of natural Ab specific
for a carbohydrate moiety present on the surface of cells from
most mammals but not from Old World primates, such as
humans (15). This moiety, Gala1-3Galb1-4GlcNAc-R (Gala1-
3Gal), is a product of the a-1-3-galactosyltransferase (GT)
enzyme that adds a terminal galactose onto glycoproteins and
glycolipids in a specific a1-3 linkage. Humans do not express a
functional GT enzyme and instead make high levels of Ab
against Gala1-3Gal as a presumed consequence of environ-
mental exposure (14, 15, 32, 39). Recent reports have shown
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that murine retroviruses and human immunodeficiency virus
(HIV) passaged through cells expressing GT assimilate Gala1-
3Gal onto the virion gp70 and gp120 envelope proteins, re-
spectively (28, 30, 36). The anti-Gala1-3Gal Ab (anti-Gal) in
NHS binds to the virion and greatly augments the ability of
complement to lyse the virion. Unquestionably, the incorpora-
tion of Gala1-3Gal onto virion surfaces by passaging retrovi-
ruses through cells expressing this carbohydrate epitope aug-
ments their reactivity with complement in NHS by binding
natural Ab, and such a host cell modification may well result in
a species-dependent barrier for their transmission.
Earlier work with other enveloped viruses, such as lympho-
cytic choriomeningitis virus (LCMV), Newcastle Disease virus
(NDV), and Sindbis virus (SV), has identified host cell modi-
fication of viruses as being important for virion reactivity with
NHS (6, 19, 41, 42). Given the new information available on
the role of anti-Gal natural Ab in complement-dependent lysis
of retroviruses, we have reevaluated the mechanisms of NHS
inactivation of a variety of other viruses that acquire their
envelopes by budding through the plasma membrane. Our
results show remarkably different patterns of inactivation, de-
pending on the virus and the cell in which it is grown.
MATERIALS AND METHODS
Immunization of mice. GT null (GT-deficient) mice were mice with the 129/Sv
(129) background derived from embryonic stem cells deleted by homologous
recombination in the GT gene (37). These mice were licensed from the Univer-
sity of Michigan and were developed in a Howard Hughes Medical Institute
Laboratory. 129 wild-type (WT) (GT-sufficient) mice used as controls were
obtained from Jackson Laboratories. GT-deficient and GT-sufficient mice were
immunized at 6 weeks of age with erythrocyte membranes isolated from fresh
rabbit blood (Cocalico Biologicals, Inc., Reamstown, Pa.). Whole blood was
centrifuged at 3,000 3 g for 10 min, and the plasma was discarded. Cells were
lysed with 0.13 phosphate-buffered saline (PBS), and membranes were pelleted
at 40,000 3 g for 30 min. The supernatant was removed, and membranes were
resuspended in 0.13 PBS and centrifuged as before. After the procedure was
carried out a third time, the membrane pellet was resuspended in 13 PBS and
again centrifuged and resuspended in PBS to give 1010 erythrocyte membranes
per ml. A total of 0.5 ml was injected intraperitoneally into each mouse. Four
total injections were given at 4-week intervals. Anti-Gal Ab levels in the mouse
sera were assayed by enzyme-linked immunosorbent assay (ELISA) using Gala1-
3Gal-conjugated bovine serum albumin (BSA) in the plate coat.
Cells. L-929, a mouse fibroblast cell line derived from C3H mice, BHK-21, a
Syrian hamster cell fibroblast line, N115, a neuroblastoma line from strain A
mice, HeLa, a human epithelial cell line, and Vero, an African green monkey
kidney cell line, are well-characterized cell lines cultivated on monolayers as
previously described (8, 42). SK-N-MC (HTB 10), a human melanoma cell line
(from the American Type Culture Collection, Rockville, Md.), was maintained as
monolayers in RPMI medium (Mediatech, Inc., Herndon, Va.) supplemented
with 10% fetal bovine serum (FBS), 100 penicillin (IU/ml), streptomycin (100
mg/ml), 2 mM glutamine, and 1 mM sodium pyruvate (R10 medium). GT-WT
and GT-KO are mouse embryonic fibroblast lines cultured from GT-sufficient
129 WT mice and GT-deficient transgenic mice, respectively. They were culti-
vated as monolayers in Dulbecco modified Eagle medium (Gibco BRL, Grand
Island, N.Y.) supplemented with penicillin, streptomycin, glutamine, pyruvate,
and 10% FBS (D10 medium) as described above.
Generation of GT-modified SK-N-MC cells. The full-length porcine GT cDNA
(39) was cloned into the pLXSN retroviral vector, and amphotropic retroviral
particles were produced through the intermediate ecotropic packaging cell line
GPE186 (23). Briefly, GPE186 cells were transfected with pLXSN containing
the GT gene (pLGTSN) or pLXSN without insert, using the calcium phosphate
method (2). Transfected cells were selected in D10 medium containing G418
(500 mg/ml, active weight). Transfectants were pooled, and a 24-h supernatant
was harvested from cells at about 90% confluence. The ecotropic virus stock was
used to transduce the amphotropic packaging cell line PA317 (26), which was
also selected as a pool in G418. A 24-h supernatant was harvested from these
cells at 90% confluence, and the supernatant was filtered through a 0.2-mm-pore-
size filter and stored at 270°C. SK-N-MC cells were transduced with pLGTSN or
pLXSN by adding 1 ml of amphotropic virus to cells in 9 ml of R10 medium
containing Polybrene (8 mg/ml). Following an overnight incubation, virus was
removed, and cells were selected as a pool in R10 medium containing G418 (500
mg/ml). The GT-modified cells were subcloned by limiting dilution and screened
for surface expression of Gala1-3Gal by fluorescein isothiocyanate (FITC) stain-
ing (see below). One clone expressing high levels of the Gala1-3Gal epitope on
its surface, designated SK-GT, was used in this study. The SK-N-MC cells
transduced with pLXSN were selected as a pool and served as control cells
(designated SK). Transduced cells were maintained in R10 medium containing
G418 (500 mg/ml).
Immunofluorescence and cell killing assays. Cells (5 3 105) were reacted with
polyclonal anti-Gal Ab (20 mg/ml) previously purified from human serum (30).
FITC-conjugated goat anti-human immunoglobulin G (IgG) and FITC-conju-
gated goat anti-human IgM (Zymed Laboratories, South San Francisco, Calif.)
were combined for use as secondary Ab (7.5 mg/ml [final concentration] for
each). Fluorescence was measured in a FACSort (Becton Dickinson Immuno-
cytometry Systems, San Jose, Calif.).
Viruses, propagation, and purification. The following viruses were used in
these studies: herpes simplex virus type 1 (HSV-1), KOS1.1 strain (3); LCMV,
Armstrong strain (8); NDV, AV strain (25); SV, originally from E. Pfefferkorn,
Dartmouth Medical School (40); and vesicular stomatitis virus (VSV), Indiana
strain (6). For purification, 75- or 150-mm2 tissue culture flasks containing about
75% confluent monolayers of SK or SK-GT cells were infected with virus as
described above and harvested at the peak of infection. On harvest, the culture
fluid was twice cleared of cell debris by centrifugation at 2,000 rpm (900 3 g) for
10 min. The supernatants were then layered onto discontinuous gradients of 25
and 75% Renografin-76 (Squibb Diagnostics, New Brunswick, N.J.) diluted in
TES buffer (0.01 M Tris-HCl, 0.1 M NaCl, 0.001 M EDTA [pH 7.4]) as described
previously (43). The samples were spun to equilibrium, and the 25%/75% inter-
phase band was recovered, diluted in TES buffer plus 0.1% BSA, and pelleted in
an SW41 Beckman centrifuge rotor at 35,000 rpm for 60 min in a Beckman
ultracentrifuge. The pellet was resuspended in a standard sodium dodecyl sul-
fate-urea acrylamide gel preparation buffer and run on gels for Western analyses.
Western blots. Gradient-purified VSV and SV were disrupted, and their pro-
teins were size fractionated via sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis on a 12% gel. Viral samples were normalized for protein content by
Coomassie blue staining of the gel. Proteins were transferred to nitrocellulose
and exposed to either IB4 lectin or antiviral Ab in Western blots as described
previously (28, 30). IB4 lectin selectively binds to Gala1-3Gal and is used like an
Ab to detect expression of this sugar (30). Monoclonal Abs (MAbs) SV2 and
SV127 to SV envelope proteins (used in combination) were a generous gift from
Diane Griffin (Johns Hopkins University), and the anti-VSV MAb, which rec-
ognizes the VSV G envelope protein, was kindly provided by Kathy Hardgrave
(Oklahoma Medical Research Foundation).
Serum inactivation studies. Virus was diluted in complete minimal essential
medium (MEM) with 10% FBS to a concentration of 105 PFU/ml, and 50 ml was
mixed with 50 ml of MEM, freshly thawed NHS, or serum whose complement was
inactivated by heating at 56°C for 30 min. Some experiments were miniaturized,
with half of each volume used. The NHS was a human serum pool (Diamedix,
Cambridge, Mass.) frozen at 270°C until use. The samples were incubated at
37°C for 45 min, 200 ml of MEM was added, and the reaction was stopped by
putting the samples on ice. The virus was then titrated directly for plaque
formation on Vero cell monolayers. In the disaccharide blocking studies, 10 ml of
virus at a titer of 5 3 105 PFU/ml was added to 40 ml of sera and 50 ml of
disaccharide diluted in Hanks balanced salt solution (HBSS). The disaccharides
were either Gala1-3Gal (Dextra Laboratories, Reading, England) or sucrose
(Sigma Chemical Co., St. Louis, Mo.) at a concentration of 10 mg/ml before
mixture (30). In some other experiments, mouse serum was substituted for NHS.
PEC. In some experiments serum-treated virus was added onto freshly isolated
129 mouse peritoneal exudate cells (PEC) previously adhered to 16-well plastic
plates 2 to 4 h before infection. The PEC had been isolated by peritoneal lavage
with RPMI 1640 and seeded at 106 cells per well. Before infection, the medium
was removed, and replaced with 1 ml of complete RPMI 1640 (R10 medium
without the pyruvate), to which virus was added in 100 ml. After a 2- to 4-h
adsorption period, the culture fluid containing unadsorbed virus was removed
and replaced with 1 ml of RPMI medium. At 22 to 26 h postinfection, the culture
fluid was harvested and used for viral titrations on Vero cell monolayers.
RESULTS
Expression of Gala1-3Gal on cell lines. We reported previ-
ously that LCMV passaged in L-929 cells, but not in N115,
HeLa, or BHK-21 cells, was effectively inactivated by NHS
(42). To determine if this pattern of serum sensitivity corre-
lated directly with Gala1-3Gal expression on the host cell
surface, these cell lines, as well as the human melanoma cell
line SK-N-MC modified to express GT, were reacted with
purified anti-Gal and analyzed by flow cytometry. As expected,
the unmodified human SK cells and human HeLa cells did not
react with anti-Gal (Fig. 1). Similarly, the hamster cell line
BHK-21, shown previously to be deficient in Gala1-3Gal ex-
pression (17), did not react with anti-Gal. In contrast, the
mouse L-929 and modified human SK-GT cells reacted
strongly with the anti-Gal. The mouse N115 cell line was
weakly positive for Gala1-3Gal expression. These cell lines
were also incubated at 37°C for 30 min with NHS, and cell
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viability was measured. There was a direct correlation between
cell surface expression of Gala1-3Gal and cell killing in NHS
(data not shown).
Inactivation of LCMV passaged through different cell lines.
Passage of LCMV through L-929 cells resulted in a virus sen-
sitive to inactivation by fresh but not heat-inactivated NHS
(Table 1, experiment 1). Our previous studies had shown that
this inactivation was mediated by an undefined natural Ab and
by the classical complement pathway, which is heat sensitive
(42). Passage of LCMV through HeLa and BHK-21 cells re-
sulted in virus that resisted inactivation by NHS. Our earlier
work also showed that passage of LCMV in N115 cells led to
virus resistant to NHS, and it is noteworthy that N115 cells only
dimly express Gala1-3Gal and are themselves resistant to lysis
by NHS (Fig. 1). Passage of LCMV through SK-GT cells re-
sulted in virus highly sensitive to inactivation, but passage of
LCMV through unmodified SK cells led to resistant virus.
These data suggest that incorporation of Gala1-3Gal onto the
virion surface renders LCMV susceptible to the anti-Gal nat-
ural Ab in NHS.
To confirm that the sensitivity of LCMV passed through
L-929 or SK-GT cells was indeed associated with the incorpo-
ration and targeting of Gala1-3Gal moieties, soluble Gala1-
3Gal was added into the inactivation assays in order to con-
sume the anti-Gal natural Ab. As controls, viruses were
incubated either with HBSS or with a control disaccharide,
sucrose. Incorporation of either disaccharide into the assays
had no effect on the serum sensitivity of LCMV passed through
SK cells (Table 1, experiment 2). Conversely, the inclusion of
soluble Gala1-3Gal markedly inhibited the serum inactivation
of LCMV passaged in SK-GT cells. The inclusion of soluble
Gala1-3Gal into assays with LCMV passaged through L-929
cells also inhibited the inactivation by NHS, though it should
be noted that in three experiments this inhibition was never as
complete as it was with virus passaged through the SK-GT cells
(Table 1, experiment 2). We interpret these experiments to
mean that the incorporation of the Gala1-3Gal epitope into
LCMV during its growth in cells renders it sensitive to anti-Gal
natural Ab-dependent complement inactivation, but the
LCMV passaged through mouse L-929 cells, unlike LCMV
passaged through human SK-GT cells, may express additional
epitopes that could also be targeted by NHS. Alternatively,
differences in the level of Gala1-3Gal incorporation into the
virion or other differences in membrane structure associated
with sensitivity to complement might have influenced the re-
sults with LCMV passaged through L-929 cells. LCMV was
therefore also passaged in cell lines derived from either a
GT-deficient mouse (GT-KO) or a GT-sufficient mouse (GT-
WT). The GT-KO cell line is a 3T3-like cell that is totally
devoid of the Gala1-3Gal epitope and completely resistant to
lysis by NHS (Fig. 1). LCMV passaged through GT-WT cells
was inactivated about 500-fold by NHS, whereas virus passaged
through GT-KO cells was very resistant (Table 1, experiment
FIG. 1. Expression of Gala1-3Gal on cultured cells. Cells used in these
experiments were stained with purified anti-Gal Ab and analyzed by flow cytom-
etry as described in Materials and Methods. Peaks depict Gala1-3Gal expression
on the surfaces of L-929, N115, HeLa, BHK-21, SK-N-MC (SK) cells or SK-
N-MC cells transduced with recombinant GT (SK-GT), and cells from GT-
deficient (GT-KO) or GT-sufficient (GT-WT) mice.
TABLE 1. Inactivation of LCMV by NHSa
Expt Virus Inhibitor
Log10 PFU after treatment
NHS Heat-inactivatedNHS MEM
1 LCMV-BHK 4.0 3.9 4.2
LCMV-HeLa 5.0 4.9 4.8
LCMV-L-929 1.5 3.9 4.2
LCMV-SK 4.3 4.5 4.5
LCMV-SK-GT 2.4 4.0 4.2
2 LCMV-L-929 HBSS ,1 3.7
Gala1-3Gal 2.5 3.9
Sucrose ,1 3.7
LCMV-SK HBSS 3.9 4.3
Gala1-3Gal 4.1 4.2
Sucrose 3.9 4.0
LCMV-SK-GT HBSS 2.0 3.8
Gala1-3Gal 3.3 3.7
Sucrose 2.0 3.7
3 LCMV-GT-WT 1.6 4.3 4.0
LCMV-GT-KO 3.4 3.6 3.4
LCMV-SK 4.2 4.2 4.1
LCMV-SK-GT 2.1 4.0 3.7
a LCMV passaged in different cell lines was treated with fresh or heat-inacti-
vated NHS or with MEM for 1 h at 37°C and titrated for PFU. In expt 2, either
HBSS, soluble Gala1-3Gal, or sucrose was included in the inactivation assay.
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3). This result indicates that Gala1-3Gal is the major target of
serum inactivation of mouse cell-passaged LCMV and that any
other targets are of minimal importance.
Replication of LCMV in mice expressing Ab to Gala1-3Gal.
To test the hypothesis that natural Ab-mediated complement
inactivation of viruses passaged through cells expressing
Gala1-3Gal may play an important role in natural resistance to
virus infections in vivo, we examined the replication of LCMV
in mice expressing Ab to this epitope. This experiment was
complicated by the fact that mice endogenously express Gala1-
3Gal and cannot be immunized against it because they are
immunologically tolerant. Passive transfer of Ab into normal
mice also is not feasible, as it would react with the recipient’s
tissues. To overcome these obstacles GT-sufficient and GT-
deficient (GT-KO) 129 mice (37) were immunized with rabbit
erythrocytes, which are a rich source of Gala1-3Gal (15). As
assessed by binding to Gala1-3Gal-conjugated BSA by ELISA
(data not shown), the GT-deficient mice developed high Ab
titers to Gala1-3Gal, equaling or surpassing the anti-Gal titers
in NHS. Both IgG and IgM anti-Gal Ab were present in the
sera of these mice. The immunized GT-sufficient mice, because
of immunological tolerance, did not make a detectable Ab
response to the epitope. These mice were inoculated with
LCMV passaged either in SK cells or in SK-GT cells and
examined for viral titers in the spleens 3 days later. The mice
received either a standard dose of 5 3 104 PFU, which we use
for assays on NK cell and cytotoxic T-cell function (8), or a
lower dose of 5 3 102 PFU, in case any effects could more
readily be seen at limiting amounts of virus. To ensure expo-
sure of virus to high concentrations of serum components,
virus was inoculated intravenously.
It was anticipated that in this experiment, LCMV passaged
through SK-GT cells would replicate poorly in the GT-defi-
cient mice expressing Ab to Gala1-3Gal, but the results failed
to support this hypothesis, as there were no particular patterns
in viral replication that could not be explained by minor dif-
ferences in input inocula of the two viral stocks (Table 2). Of
further note is that the individual Ab-positive GT-deficient
mice had over fivefold variations in their Ab titers (data not
shown), but the reproducibility in viral titers within that group
of mice was extremely high, as shown by the very low standard
deviation, and did not correlate at all with the Ab titers.
This result led us to question whether our fundamental hy-
pothesis was wrong or whether mouse serum lacked the capac-
ity to inactivate LCMV even in the presence of Ab to the
Gala1-3Gal epitope. Therefore, in vitro assays were performed
to assess the ability of anti-Gal in the serum from GT-deficient
mice to neutralize LCMV passaged in cells expressing Gala1-
3Gal. Fresh serum from Ab-positive mice reduced the infec-
tivity of LCMV passaged in SK-GT cells as measured by PFU
in Vero cells by 0.7 to 0.8 log10 compared to the normal mouse
serum controls (Table 3, experiments 1 and 2). Under the same
conditions, NHS more dramatically reduced LCMV infectivity,
by 1.3 to 1.6 log10 PFU. Although the NHS was frozen and
thawed before use, the mouse immune serum needed to be
freshly isolated to have any significant antiviral activity. After
one freeze-thaw, the immune mouse serum lost its ability to
inactivate LCMV, even though it could still mediate the inac-
tivation of LCMV by a guinea pig serum complement (gp C)
source (e.g., inactivation of LCMV passaged in SK-GT cells
[log10 PFU]: MEM, 3.7; control mouse serum, 3.6; immune
mouse serum, 3.5; gp C, 3.7; immune mouse serum plus gp C,
2.9). This result demonstrates the well-known phenomenon
that complement levels from laboratory mouse strains are
quite low and lose activity after freeze-thawing (46). The ability
of the immune mouse serum to sensitize virus to inactivation
by gp C-containing serum is evidence that the mouse serum
contains anti-Gal Ab that survived the freeze-thaw cycle.
These experiments showed that freshly isolated immune
mouse sera could inactivate LCMV passed through SK-GT
cells, even though the levels were not as profound as with NHS.
However, if aliquots from these same serum-treated viral prep-
arations were used to initiate infection of adherent PEC, only
the treatment with NHS caused an inhibition in the 24-h yield
(Table 3, experiments 1 and 2). In the two experiments shown,
NHS completely eliminated the 24-h yield of LCMV passaged
through SK-GT cells but had no effect on LCMV passed
through SK cells. In contrast, the 24-h yield of LCMV passaged
through SK-GT cells and exposed to anti-Gal-Ab-containing
fresh mouse serum was indistinguishable from the titers in
control samples. Macrophages, which have receptors for
mouse Ab and complement, are a primary target for the
LCMV infection in vivo (24), and it appears that exposure of
TABLE 2. Replication of LCMV in mice containing Anti-Gal Aba
Virus Dose
Log10 PFU/spleen (mean 6 SD)
GT-sufficient
(Ab2) mice
GT-deficient
(Ab1) mice
LCMV-SK 5 3 104 6.5 6 0.15 6.1 6 0.19
LCMV-SK-GT 5 3 104 5.7 6 0.03 5.5 6 0.06
LCMV-SK 5 3 102 5.2 6 0.13 4.6 6 0.03
LCMV-SK-GT 5 3 102 4.0 6 0.13 3.4 6 0.01
a Mice were immunized with sheep erythrocyte membranes to induce Ab to
Gala1-3Gal. No Abs were detected in immunized GT-sufficient 129 WT mice,
but high titers were elicited in GT-deficient (GT-KO) mice, which recognize
Gala1-3Gal as a foreign antigen. Mice were inoculated intravenously with 5 3
104 (n 5 4 per group) or 5 3 102 (n 5 2 per group) PFU of LCMV passaged in
SK or SK-GT cells and titrated for PFU/spleen at 3 days postinfection.
TABLE 3. Inactivation of LCMV with immune mouse seruma
Expt Virus Treatment
Log10 PFU
Direct
assay
PEC
yield
1 LCMV-SK NHS 3.7 3.5
MEM 3.8 3.3
GT-def 1 (Ab1) 3.8 3.5
GT-def 2 (Ab1) 3.8 3.6
GT-suf (Ab2) 3.7 3.5
LCMV-SK-GT NHS 1.7 ,1
MEM 3.0 2.1
GT-def 1 (Ab1) 2.5 2.5
GT-def 2 (Ab1) 2.5 2.7
GT-suf (Ab2) 3.3 2.8
2 LCMV-SK NHS 3.9 2.0
DNHS 4.0 2.3
MEM 4.2 2.4
GT-def (Ab1) 4.1 2.7
GT-suf (Ab2) 4.0 3.2
LCMV-SK-GT NHS 2.3 ,1
DNHS 3.8 2.3
MEM 3.9 2.6
GT-def (Ab1) 3.1 2.1
GT-suf (Ab2) 3.8 2.4
a LCMV passaged in different cell lines was treated with NHS, heat-inacti-
vated NHS (DNHS), MEM, or serum from GT-sufficient 129 WT (GT-suf) or
GT-deficient (GT-def) mice. All mice had been previously immunized against
sheep erythrocytes, but only the GT-deficient mice developed anti-Gal Ab re-
sponses. Samples were either titrated directly on Vero cells or used to infect 129
mouse PEC. Virus released into the PEC culture fluid 1 day postinfection was
then titrated for PFU on Vero cells.
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LCMV to the immune mouse serum could not block its infec-
tion of macrophages, which are the predominant cell in the
adherent PEC population. These results indicate that natural
Ab to Gala1-3Gal by itself is insufficient to control infection by
a virus expressing the epitope and that a potent complement
source may be needed for the efficacy of the Ab in vivo. The
results also indicate that the inactivation of LCMV by mouse
serum containing anti-Gal Ab is unlikely to be due to a virolytic
mechanism, as a lysed virus would not maintain its infectivity
for macrophages.
Patterns of inactivation of other enveloped viruses. An eval-
uation of NHS inactivation of other enveloped viruses puta-
tively modified by passage through cells either expressing or
not expressing the Gala1-3Gal epitope was performed, and
different patterns of inactivation were noted (Table 4). HSV
passaged in either SK-GT or unmodified SK cells was totally
inactivated by NHS, and this inactivation did not require com-
plement, as heat-inactivated NHS also completely inactivated
the virus (Table 4, experiment 1). This result could be ex-
plained by the fact that HSV is a ubiquitous human virus, and
NHS contain high levels of anti-HSV neutralizing antibodies.
The presence of anti-HSV Ab in a separately tested NHS
preparation that gave the same pattern of inactivation was
confirmed by exposing HSV-infected SK cells to NHS followed
by an FITC-labeled anti-human Ig. We present these data with
HSV to contrast them to studies with viruses that are not
ubiquitous human pathogens. VSV, which has previously been
shown to be inactivated by the classical complement pathway
mediated by autologous natural Ab (6), was inactivated by
NHS, regardless of the passage history of the virus (Table 4,
experiments 1, 2, and 4). In contrast to HSV, heat inactivation
of the serum considerably reduced the inactivation, suggesting
a complement-mediated event. Similarly, NDV, which previ-
ously has been shown to be inactivated by the alternative com-
plement pathway in the absence of Ab (41, 42), was inactivated
over 100-fold by fresh NHS but not by heat-inactivated serum,
again regardless of its passage history. Previous work with
NDV has shown that host modification of the virus plays a role
in its sensitivity to lysis by NHS (41), but in this case the virus
was grown in similar cell lines either expressing Gala1-3Gal or
not, and that defined variable did not alter the sensitivity of
NDV to inactivation. NDV and VSV both had patterns of
inactivation distinct from those of LCMV and the retroviruses,
but SV demonstrated yet another pattern. SV passed through
either SK-GT or SK cells resisted inactivation by NHS. Host
modification of sialic acid determinants on SV has previously
been implicated in its ability to activate human or gp C (19),
but here it is clear that modulating only the cell expression of
Gala1-3Gal did not affect the resistance of SV to neutraliza-
tion by NHS.
The apparent indifference of SV and VSV to passage in SK
cells lacking or expressing Gala1-3Gal led us to question
whether Gala1-3Gal was excluded from their virion surfaces.
Western blot analyses were performed on purified virus, using
either a lectin specific for the Gala1-3Gal epitope (IB4 lectin)
or Ab to the viral envelope proteins. VSV passaged through
SK-GT cells but not through SK cells contained a Gala1-3Gal-
expressing protein of about 70 kDa (Fig. 2). This represents
the major VSV envelope glycoprotein G, as demonstrated by
its reactivity with Ab to G protein (12). VSV passed through
SK cells expressed the 70-kDa G protein but did not react with
the lectin. Examination of SV passed through SK-GT cells
revealed a 53-kDa protein expressing Gala1-3Gal. The reac-
tivity of a MAb pool to the SV envelope proteins indicated that
this band represents the major glycosylated envelope protein
E2 of SV (21, 33). Of interest is that the incorporation of
Gala1-3Gal into the SV envelope protein may have altered its
processing, as the protein appeared as a double band with
SK-GT-passaged SV but a single band with SK-passaged SV.
We have not further investigated this observation. Thus, both
VSV and SV were shown to incorporate the Gala1-3Gal de-
terminant onto virion glycoproteins, yet the presence of this
epitope did not influence their inactivation by or resistance to
NHS. Preliminary observations with the more difficult to purify
(from these cells) LCMV revealed an IB4 lectin-binding band
in the position of the LCMV GP1 protein. Because the reac-
tivity of LCMV with Ab to Gala1-3Gal appeared quite clear in
our inactivation studies, we have not further analyzed the
LCMV virion for its incorporation of the moiety.
FIG. 2. Expression of Gala1-3Gal on virion proteins. Purified SV (A and B)
and VSV (C and D) passaged in SK-GT (lanes 1) or SK (lanes 2) cells were
analyzed by Western blotting for expression of viral envelope proteins by binding
of anti-viral Ab (B and D) or for expression of Gala1-3Gal by binding of IB4
lectin (A and C) as described in Materials and Methods. Sizes are indicated in
kilodaltons.
TABLE 4. Inactivation of heterologous viruses by NHSa
Expt Virus
Log10 PFU after treatment
NHS
Heat-
inactivated
NHS
MEM
1 HSV-SK ,1 ,1 3.5
HSV-SK-GT ,1 ,1 .3.7
SV-SK 3.2 3.5 3.6
SV-SK-GT 3.4 3.3 3.3
VSV-SK 2.2 3.6 4.1
VSV-SK-GT 2.0 4.0 3.9
2 NDV-SK 1.8 3.8 3.7
NDV-SK-GT ,1 3.9 4.2
SV-SK 3.4 3.6 3.5
SV-SK-GT 3.5 3.4 3.7
VSV-SK 2.2 3.6 4.3
VSV-SK-GT 1.8 3.9 4.0
3 NDV-SK-STOCK 1 ,1 3.0 3.1
NDV-SK-STOCK 2 1.7 4.0 4.1
NDV-SK-GT-STOCK 1 ,1 3.4 3.4
NDV-SK-GT-STOCK 2 1.5 4.1 4.2
4 SV-GT-WT 2.9 4.1 4.2
SV-GT-KO 4.2 4.4 4.4
VSV-GT-WT ,1 4.0 4.1
VSV-GT-KO 1.0 4.0 4.1
5 SV-GT-WT 3.5 4.0 4.3
SV-GT-WT 1 nanase 3.4 4.3 4.4
SV-GT-KO 4.2 4.3 4.4
SV-GT-KO 1 nanase 3.8 4.1 4.2
SV-SK 3.9 3.8 3.8
SV-SK 1 nanase 4.2 3.9 4.0
SV-SK-GT 3.6 3.7 3.7
SV-SK-GT 1 nanase 3.8 3.8 3.7
a Viruses passaged through human SK and SK-GT or mouse GT-KO and
GT-WT cells were treated with sera as described in Materials and Methods and
assayed for PFU on Vero cell monolayers. In experiment 5, viruses, where
designated, were incubated 1:1 with 0.3 U of Clostridium perfringens neuramin-
idase (nanase) (Sigma) per ml for 1 h at 37°C before treatment with sera.
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Given that host cell differences have previously been corre-
lated with the ability of SV to activate complement in the
absence of Ab (19) and some viruses have been shown to
incorporate anti-complement regulatory proteins into their
virions when passaged through certain human cell lines (27),
we examined the inactivation of SV passaged through mouse
GT-WT and GT-KO cell lines. After this passage, the inacti-
vation of SV resembled that of LCMV in that SV passaged
through the GT-WT cells was inactivated, whereas SV pas-
saged through GT-KO cells was resistant (Table 4, experiment
4). The inactivation of SV passaged through GT-WT cells by
NHS was not as pronounced as the inactivation of LCMV
passaged through the same cells, but it was nevertheless sig-
nificantly different from the inactivation of SV passed through
SK-GT cells. To determine if this sensitivity to inactivation
may have been due to differences in sialic acid content between
the human and mouse cell lines, SV passaged through these
lines was treated 1:1 with 0.3 U of neuraminidase per ml before
exposure to NHS. Although 0.5 ml of this same neuraminidase
solution removed a sialic acid-dependent CD45 epitope from
splenocytes (detectable by MAb CZ-1 [7]) (data not shown),
the treatment of SV in the present experiment had no signif-
icant effect on the pattern of viral inactivation (Table 4, exper-
iment 5).
DISCUSSION
It is well established that enveloped viruses assimilate virtu-
ally unmodified cellular lipids into their virions and that their
glycoproteins have glycosylation patterns similar to those of
the glycoproteins of the cells in which they are passaged (29).
It would therefore be expected that viruses passaged through
cells containing a functional GT and expressing Gala1-3Gal
should themselves express this carbohydrate epitope, and data
shown here for VSV and SV (Fig. 2) and published elsewhere
for HIV (28) and murine retroviruses (30, 36) support this
conclusion. What is surprising is that the various enveloped
viruses studied displayed different patterns of inactivation by
NHS. LCMV was similar to the retroviruses in that Ab to
Gala1-3Gal greatly augmented its inactivation by complement
in NHS. In contrast, SV passed through GT-expressing human
cells was resistant to inactivation by NHS, while NDV and
VSV were inactivated by NHS, regardless of whether the
Gala1-3Gal epitope was present.
Factors involved in Ab and complement inactivation of vi-
ruses include the amount of Ab bound to the virion, the prox-
imity of Ab binding to the lipid bilayer (1), whether comple-
ment regulatory factors are incorporated into the virion (27),
and the nature of virion lipid and carbohydrate structures
(which could be influenced by the type of cellular membrane
through which the virion buds and by such factors as the degree
of sialation) (19, 21, 29). The fact that NDV and VSV were
inactivated by NHS regardless of their modification with
Gala(1-3)Gal can be explained by previous work showing that
NDV can directly activate complement in the absence of Ab
(41, 42) and that VSV binds to a distinct human natural IgM
Ab that remains undefined but, based on the present study, is
probably not specific for Gala1-3Gal (6). An explanation for
the resistance of SV to NHS, even after it has incorporated
Gala1-3Gal into its virion, is more problematic. Previous work
has shown that SV could be lysed by complement in the pres-
ence of antiviral Ab (35). Other work showed that purified SV
virions could activate the complement system in the absence of
Ab, that the levels of activation depended on the cells through
which SV was passaged, and that the activation was signifi-
cantly enhanced by treatment of the virions with neuramini-
dase to cleave off sialic acid determinants (19). In this present
study, neuraminidase treatment of SV passed through SK-GT
cells did not render the virions significantly more sensitive to
NHS (Table 4, experiment 5), suggesting that high levels of
sialation were not responsible for its resistance to lysis. Al-
though SV virions acquire host cell plasma membrane lipids
and glycosylation patterns, the ratio of cholesterol to phospho-
lipids is much higher than in cell membranes, and the SV
membranes are more densely packed, less fluid, and have
greater curvature than cellular membranes (21, 22, 29). It is
possible that these properties contribute to the resistance of
the virus to inactivation by NHS. Additionally, some viruses,
such as HIV, acquire species-restricted complement regulatory
factors from the cells through which they are passed (27). We
detected significant expression of the complement regulatory
factors CD55 and CD59 on SK-N-MC cells by immunofluo-
rescence (data not shown). This seemed like an unlikely mech-
anism to explain the resistance of SV to inactivation by NHS,
because the SK-GT cells themselves were quite sensitive to
lysis (Fig. 2). Nevertheless, we examined the sensitivity of SV
passaged through mouse GT-WT cells to NHS and found that
it was sensitive to inactivation. Whether this means that SV
acquired species-restricted anti-complement factors from hu-
man SK-GT cells but not from mouse GT-KO cells remains
unresolved, but it demonstrates further the complexity of host
modification factors determining whether or not a given virus
is sensitive to inactivation by NHS.
The availability of GT-deficient mice, which can be immu-
nized to mount Ab responses to Gala1-3Gal, led us to test our
hypothesis that species-dependent differences in natural Abs to
cellular membranes may play important roles in natural immu-
nity against enveloped viruses (42). However, even though sera
from the immunized mice had some moderate antiviral activity
against LCMV passaged through GT-expressing cells, immune
mice did not restrict the replication of that virus in vivo. Work
on Ab-independent complement activation by human retrovi-
ruses has shown that the activation of complement through this
mechanism is insufficient to trigger virolysis and consequently
serves as an opsonin for viral infection of cells expressing CR
(38). We therefore questioned whether the inactivation of
LCMV vis a` vis its growth in vero cells would be equivalent to
its inactivation vis a` vis its growth in macrophages, which ex-
press Fc receptors and CR and are the natural targets for
LCMV in vivo (24). Table 3 shows that treatment with the
same mouse sera that inhibited virus growth on Vero cells did
not inhibit the viral infectivity on PEC. Complement levels in
laboratory mice are much lower than in wild mice, guinea pigs,
rabbits, or humans, and infectious virus-Ab-complement com-
plexes can be isolated from the sera of LCMV persistently
infected mice (46). Thus, the GT-deficient mouse model, due
to its low complement activity, may not be an appropriate
model to test the role of anti-Gal in immunity to viruses cross-
ing species barriers, despite mounting anti-Gal Ab titers sim-
ilar to that in humans. This model does, however, illustrate the
probable importance of a highly efficient complement source,
as the anti-Gal Ab that was present could apparently bind to
the LCMV virions but was ineffective in the weak complement
milieu of the mouse. The importance of complement in the
control of viral infections has further been illustrated in studies
in animals depleted of complement components (18) and is
predicted by the observations that many viruses encode CR or
complement regulatory proteins and that some viruses incor-
porate cellular complement regulatory proteins into their
membranes (9, 27, 31).
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